In this article, we will take a look at the 10 Best Pharma Stocks To Buy Right Now.

Earlier this year, BMY completed a $14 billion acquisition of Karuna Therapeutics, gaining access to its experimental ...

Two Key Executive Hires for Organizational Capabilities and GrowthCAMBRIDGE, Mass., Oct. 31, 2024 (GLOBE NEWSWIRE) -- Anthos ...

BioSpace has been compiling a list of the most innovative and exciting biotechs for a decade. Here we take a look back at ...

The funding for Axonis, which is developing novel medicines for pain and epilepsy, reflects growing confidence in precision ...

Click Therapeutics, Croium, Emalex, Idorsia, Karuna, Lumos Labs, Medgenics, Neurocrine, NLS Pharma, Sirtsei, and Sumitomo.

Big-name venture capital firms are raising billions again, though funding a small number of de-risked companies. Meanwhile, ...

Q3 2024 Earnings Call Transcript October 31, 2024 Bristol-Myers Squibb Company beats earnings expectations. Reported EPS is ...

Bristol-Myers Squibb has decided to gamble on the FDA approving Karuna Therapeutics’ schizophrenia drug candidate KarXT next year, agreeing to buy the company for approximately $14 billion.

Bristol Myers Squibb Co. raised its 2024 earnings guidance after reporting better-than-expected revenue and profit, fueled by ...